Tumor-Directed and Alloreactive T-Cells Synergize in the Rejection of Mouse Prostate Cancer - joint IBI & ISREC seminar
Event details
| Date | 11.06.2013 |
| Hour | 11:00 › 12:00 |
| Speaker |
Anna Mondino, PhD, San Raffaele Scientific Institute, Milan (I) Bio: 1988 Master in Biological Sciences, University of Turin, Italy 1992 Ph.D., Molecular Oncology, University of Turin, Italy Research and professional experience: 1986-1988 - Undergraduate student 1988-1989 - Research Fellow, AIRC 1989-1991 - Ph.D. student in Molecular Oncology Department of Biomedical Science and Oncology, Turin, Italy 1991-1992 - Ph.D. student in Molecular Oncology Dr. Schlessinger' s lab, Department of Pharmacology New York University, Medical Center, New York, USA 1993-Feb. 1998 - Postdoctoral Associate Department of Microbiology University of Minnesota, Medical School, Minneapolis, MN, USA April 1998-1999 - Research Associate Department of Molecular Pathology and Medicine DIBIT/ H. S. Raffaele, Milan, Italy Since January 2000 - Principal Investigator Lymphocyte Activation Unit Cancer Immuno-therapy and Gene Therapy Program Department of Immunology and Infectious Diseases DIBIT/ San Raffaele Scientific Institute, Milan, Italy |
| Location | |
| Category | Conferences - Seminars |
We are interested in the cellular and molecular mechanisms dictating protective immunity against malignant tumors. We have adopted the Transgenic Adenocarcinoma of the Mouse Prostate cancer (TRAMP) model, which closely recapitulate prostate cancer occurrence and progression in humans, to design, test and validate innovative immunotherapeutic strategies suitable of clinical translation. Results describing the therapeutic efficacy obtained by combining tumor and alloreactive T cells in the contest of hematopoietic cell allotransplantation and of adoptive T cell therapy with autologous TCR gene engineered T cells will be discussed.